RIVANNA Expands Accuro XV Clinical Program and Targets Faster 510(k) Pathway

According to a recent LinkedIn post from RIVANNA, the company’s clinical program for its Accuro XV volumetric ultrasound system has expanded from two to eight sites across the U.S. in four months, with 10 systems now deployed at leading academic medical centers. Participating institutions include Denver Health, Texas Tech Health El Paso, UCSF, University of Utah, UVA Health, UT Southwestern, Virginia Commonwealth University, and Yale, with all sites reported as actively enrolling patients.

The post indicates that this broader enrollment is intended to accelerate development of Accuro XV’s AI-enabled fracture detection and may compress the expected 510(k) submission timeline. Accuro XV is described as a portable, point-of-care imaging system aimed at supporting fracture care at triage, potentially streamlining emergency department workflows and reducing reliance on ionizing radiation for low-severity extremity injuries.

RIVANNA’s post notes that 666 patients have been enrolled to date, with preliminary analysis from a subset suggesting possible patient experience benefits in addition to the diagnostic capabilities under development, though these findings have not yet been published. For investors, faster clinical progress and regulatory preparation could shorten time to market, but the impact will depend on eventual clinical validation, regulatory review outcomes, and health system adoption.

The expansion of the clinical program is linked in the post to the execution of a funding option by BARDA, part of ASPR within the U.S. Department of Health and Human Services. This association with a U.S. government preparedness agency may be viewed as a validation of the technology’s potential relevance for emergency and surge-care settings, and it could support RIVANNA’s positioning in the medtech and point-of-care ultrasound markets if Accuro XV advances successfully through regulatory and commercialization stages.